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With the increasing amount of evidence linking certain disorders of the human body to
a disturbed gut microbiota, there is a growing interest for compounds that positively
influence its composition and activity through diet. Besides the consumption of
probiotics to stimulate favorable bacterial communities in the human gastrointestinal
tract, prebiotics such as inulin-type fructans (ITF) and arabinoxylan-oligosaccharides
(AXOS) can be consumed to increase the number of bifidobacteria in the colon.
Several functions have been attributed to bifidobacteria, encompassing degradation
of non-digestible carbohydrates, protection against pathogens, production of vitamin
B, antioxidants, and conjugated linoleic acids, and stimulation of the immune system.
During life, the numbers of bifidobacteria decrease from up to 90% of the total colon
microbiota in vaginally delivered breast-fed infants to <5% in the colon of adults and
they decrease even more in that of elderly as well as in patients with certain disorders
such as antibiotic-associated diarrhea, inflammatory bowel disease, irritable bowel
syndrome, obesity, allergies, and regressive autism. It has been suggested that the
bifidogenic effects of ITF and AXOS are the result of strain-specific yet complementary
carbohydrate degradation mechanisms within cooperating bifidobacterial consortia.
Except for a bifidogenic effect, ITF and AXOS also have shown to cause a butyrogenic
effect in the human colon, i.e., an enhancement of colon butyrate production. Butyrate
is an essential metabolite in the human colon, as it is the preferred energy source for
the colon epithelial cells, contributes to the maintenance of the gut barrier functions,
and has immunomodulatory and anti-inflammatory properties. It has been shown that
the butyrogenic effects of ITF and AXOS are the result of cross-feeding interactions
between bifidobacteria and butyrate-producing colon bacteria, such as Faecalibacterium
prausnitzii (clostridial cluster IV) and Anaerostipes, Eubacterium, and Roseburia species
(clostridial cluster XIVa). These kinds of interactions possibly favor the co-existence
of bifidobacterial strains with other bifidobacteria and with butyrate-producing colon
bacteria in the human colon.
Keywords: bifidobacteria, butyrate-producing colon bacteria, cross-feeding, prebiotics, probiotics,
arabinoxylan-oligosaccharides, inulin-type fructans
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INTRODUCTION
Whereas, the human gut microbiota has been studied in
the past mainly in the context of infectious diseases, it is
known today that this enormous number of microorganisms
has an indispensable role in the normal development and
functioning of the human body (O’Hara and Shanahan, 2006;
Sommer and Bäckhed, 2013). Within the adult gastrointestinal
tract, the colon contains the most dense (>1011 bacteria per
mL of luminal content) and metabolically active microbiota
(Figure 1; Whitman et al., 1998; The Human Microbiome
Project Consortium, 2012). The immense number of genes
(>100 times the number of genes of the human genome)
encoded by this microbiota, expands the host’s biochemical
and metabolic capabilities substantially (Bäckhed et al., 2005;
The Human Microbiome Project Consortium, 2012). Examples
of supporting functions of the human gut microbiota are
the degradation of otherwise non-digestible food compounds;
the transformation of toxic compounds; and the production
of essential vitamins, important metabolic end-products, and
defending bacteriocins (Sommer and Bäckhed, 2013). Microbial
metabolic end-products, which account for one third of the
metabolites present in the human blood, play an important role
in gut homeostasis and have an impact on host metabolism and
health (Wikoff et al., 2009; Hood, 2012; Louis et al., 2014; Sharon
et al., 2014; Richards et al., 2016). The short-chain fatty acids
(SCFAs) acetate, butyrate, and propionate (typically occurring
in a 3:1:1 ratio) are quantitatively (total concentration of 50–
150 mM) and metabolically the most important microbial end-
products of the human colon fermentation process (Louis et al.,
2014), as they display several physiological effects (Table 1).
Changes in the gut microbiota composition have been
associated with disturbed gut barrier functions, increased
gut permeability, and increased plasma lipopolysaccharide
concentrations (i.e., metabolic endotoxemia), which causes low-
grade inflammation that triggers the development of obesity and
metabolic syndrome (Cani et al., 2008). Also other disorders,
such as inflammatory bowel disease (IBD, encompassing Crohn’s
disease and ulcerative colitis), irritable bowel syndrome (IBS),
colorectal cancer, and allergies have been linked to changes in
the gut microbiota composition (de Vos and de Vos, 2012; Le
Chatelier et al., 2013). During the last years, even associations
have been made between the gut microbiota composition
and behavioral disorders, such as depression, anxiety disorder,
regressive autism, and schizophrenia (Collins et al., 2012;
Braniste et al., 2014; Dinan et al., 2015). However, whereas
increasing numbers of animal studies provide evidence for
cause-and-effect relationships between shifts in gut microbiota
composition and certain disorders (as in the case of obesity;
Ridaura et al., 2013), it has not been proven yet for humans
whether changes in the gut microbiota composition can cause
disorders or that these changes are a consequence of the disorders
themselves (de Vos and de Vos, 2012).
In recent years, a few distinct members of the human gut
microbiota have received particular attention because of their
dedicated metabolism and central role in gut homeostasis
and because their loss adversely affects the remaining
microorganisms and/or host’s health. Bifidobacterium species
are one such bacterial species that fulfill important functions
within the human colon (Leahy et al., 2005; Rossi and Amaretti,
2011). Decreased numbers of these species in the colon have
been associated with several disorders. Moreover, they have
shown to interact with other colon bacteria such as butyrate-
producing bacteria by cross-feeding interactions. Furthermore,
decreased butyrate concentrations and decreased numbers of
butyrate producers in the human colon have been associated
with disorders. Therefore, this knowledge has encouraged the
development of approaches to stimulate the growth and/or
activity of bifidobacteria, i.e., the bifidogenic effect, and
butyrate-producing colon bacteria, i.e., the butyrogenic effect,
in the human colon. The most prevalent approaches to cause
bifidogenic and butyrogenic effects involve the consumption of
probiotics and prebiotics.
BIFIDOBACTERIA AND
BUTYRATE-PRODUCING COLON
BACTERIA
Bifidobacterium Species
General Aspects
Bifidobacteria are Gram-positive, anaerobic, saccharolytic
bacteria that belong to the phylum Actinobacteria; they mainly
occur in the gastrointestinal tract of mammals, birds, and insects,
but are present in sewage, human breast milk, fermented milk,
cheeses, and water kefir too (Bottacini et al., 2014; Khodayar-
Pardo et al., 2014; Laureys and De Vuyst, 2014; Laureys et al.,
2016). A typical bifidobacterial genome has an average size
ranging from 2.0 to 2.8 Mb and is characterized by a high
guanine-plus-cytosine content, with numerous genes involved
in the uptake and breakdown of carbohydrates from both diet
and host origin (Ventura et al., 2014). Bifidobacteria are among
the first bacteria to colonize the human gastrointestinal tract and
reach their highest proportion in the colon (up to 90% of the total
colonmicrobiota in vaginally delivered breast-fed infants) during
the first 12 months of life (Tannock, 2010; Turroni et al., 2012).
This abundance significantly decreases over time to<5% in adult
subjects and decreases even more in the elderly (Arumugam
et al., 2011; Duncan and Flint, 2013). At the time of writing,
the Bifidobacterium genus comprised 51 species (Euzéby, 1997,
2016; Laureys et al., 2016), among which Bifidobacterium
longum, Bifidobacterium animalis, Bifidobacterium
adolescentis, Bifidobacterium bifidum, Bifidobacterium
catenulatum, Bifidobacterium pseudocatenulatum,
Bifidobacterium breve, Bifidobacterium pseudolongum,
Bifidobacterium gallicum, Bifidobacterium angulatum, and
Bifidobacterium faecale are encountered in the human colon
(Turroni et al., 2009; Ventura et al., 2011; Choi et al., 2014). In
general, B. bifidum and B. longum are the dominant species in
infants, whereas B. adolescentis and B. longum dominate the
adult gut microbiota (Turroni et al., 2012). Quantitative PCR
analyses of fecal samples of 42 Belgian healthy adults have shown
that the fecal microbiota of adults contains between zero and
four (with an average of two) different bifidobacterial species,
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FIGURE 1 | Spatial distribution and concentrations of bacteria along the gastrointestinal tract of humans (Tuohy and Scott, 2015). The dominant genera
in the stomach, small intestine, and colon are listed, based on 16S rRNA gene sequence studies (Tap et al., 2009; Zoetendal et al., 2012; Delgado et al., 2013; Walker
et al., 2014).
among which B. longum (present in 90% of the adults), B.
adolescentis (present in 79% of the adults), and B. catenulatum
(present in 38% of the adults) are the most frequently detected
species (Ishikawa et al., 2013).
Functional Role in the Colon
From the growing body of scientific evidence associating
decreased numbers of bifidobacteria with disorders, it emerges
that these species have a disproportionally large impact in
the human colon in relation to their relatively low numerical
abundance in adults. Hence, a decrease in the relative
abundances of Bifidobacterium species in the human colon
has been associated with antibiotic-associated diarrhea, IBS,
IBD, obesity, allergies, and regressive autism (Di Gioia et al.,
2014; Grimm et al., 2014). Examples of functions carried out
by bifidobacteria include the production and/or liberation of
B vitamins, antioxidants, polyphenols, and conjugated linoleic
acids; maturation of the immune system during early life and
preservation of immune homeostasis during life; preservation
of gut barrier functions and protection against pathogens by
producing bacteriocins, decreasing luminal pH by the production
of acids, and blocking the adhesion of pathogens to the intestinal
mucosa (Leahy et al., 2005; Gorissen et al., 2010, 2012; Rossi
and Amaretti, 2011; Gagnon et al., 2015). However, these
functions are not characteristic for the Bifidobacterium genus or
certain species, but are rather strain-specific. Another important
function of the bifidobacterial genus that contributes to gut
homeostasis and host health is the production of acetate and
lactate during carbohydrate fermentation, organic acids that in
turn can be converted into butyrate by other colon bacteria
through cross-feeding interactions (Table 1; De Vuyst and Leroy,
2011; De Vuyst et al., 2014; Rivière et al., 2015).
Metabolism
Bifidobacteria display a strictly fermentative metabolism, i.e.,
they gain energy in the form of ATP by substrate-level
phosphorylation during anaerobic carbohydrate breakdown, and
play an important role in the human colon with respect to
the degradation of carbohydrates that resist digestion and
absorption in the upper gastrointestinal tract (Pokusaeva et al.,
2011; De Vuyst et al., 2014). Glycoside hydrolases (EC 3.2.1.x)
constitute the most important enzyme group that colon bacteria
use to degrade poly- and oligosaccharides to fermentable
monosaccharides (van den Broek et al., 2008; van den Broek
and Voragen, 2008). Compared with the human genome,
encoding only 17 glycoside hydrolases for the digestion of food
carbohydrates, bifidobacterial genomes possess high numbers
of genes encoding these carbohydrases (El Kaoutari et al.,
2013). As an example, the genome of B. longum NCC2705
contains 56 genes encoding glycoside hydrolases, one gene
encoding a carbohydrate esterase (EC 3.1.1.x), but no genes
encoding polysaccharide lyases (EC 4.2.2.x; Schell et al., 2002;
Lombard et al., 2014). Bifidobacteria are particularly specialized
in efficient uptake of short oligosaccharides into the cell, where
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TABLE 1 | Overview of the physiological effects of the short-chain fatty acids (SCFAs) acetate, propionate, and butyrate produced by human colon
bacteria (Hamer et al., 2008; Al-Lahham et al., 2010; Havenaar, 2011; Macfarlane and Macfarlane, 2012; Chang et al., 2014; Louis et al., 2014; Tralongo
et al., 2014).
SCFA Physiological effect
Acetate CH3-COO
− Reaches the portal vein and is metabolized in various tissues
Intestinal effects
Is a minor energy source for the colon epithelial cells
Decreases the pH of the colon (which decreases bile salt solubility, increases mineral absorption, decreases ammonia
absorption, and inhibits growth of pathogens)
Has anti-inflammatory effects
Increases colonic blood flow and oxygen uptake
Is used by cross-feeding species as a co-substrate to produce butyrate
Other effects
Is a substrate for cholesterol and fatty acid biosynthesis in the liver
Is an energy source for muscle and brain tissue
Propionate CH3-CH2-COO
− Reaches the portal vein and is subsequently taken up by the liver
Intestinal effects
Is a minor energy source for the colon epithelial cells
Decreases the pH of the colon (which decreases bile salt solubility, increases mineral absorption, decreases ammonia
absorption, and inhibits growth of pathogens)
Prevents proliferation and induces apoptosis of colorectal cancer cells
Interacts with the immune system
Has anti-inflammatory effects
Other effects
Promotes satiety
Lowers blood cholesterol levels
Decreases liver lipogenesis
Improves insulin sensitivity
Butyrate CH3-CH2-CH2-COO
− Is mainly taken up by the colon epithelial cells, only small amounts reach the portal vein and the systemic circulation
Intestinal effects
Is the preferred energy source for the colon epithelial cells
Decreases the pH of the colon (which decreases bile salt solubility, increases mineral absorption, decreases ammonia
absorption, and inhibits growth of pathogens)
Stimulates proliferation of normal colon epithelial cells
Prevents proliferation and induces apoptosis of colorectal cancer cells
Affects gene expression of colon epithelial cells
Plays a protective role against colon cancer and colitis
Improves the gut barrier function by stimulation of the formation of mucin, antimicrobial peptides, and tight-junction proteins
Interacts with the immune system
Has anti-inflammatory effects
Stimulates the absorption of water and sodium
Reduces oxidative stress in the colon
Other effects
Promotes satiety
they are further degraded to monosaccharides, i.e., they display
a preferential oligosaccharide metabolism, providing them a
competitive advantage toward other colon bacteria that degrade
carbohydrates extracellularly (Van derMeulen et al., 2004, 2006b;
Falony et al., 2009a; De Vuyst and Leroy, 2011; De Vuyst et al.,
2014). About 5% of the total bifidobacterial gene content is
dedicated to carbohydrate internalization, through either ATP-
binding cassette transporters, permeases, or proton symporters
(Ventura et al., 2009). For example, B. longumNCC2705 contains
15 genes that encode transport systems that could be involved in
the transport of oligosaccharides (Schell et al., 2002; Parche et al.,
2007). Several laboratory fermentation studies have shown that
bifidobacteria can use various non-digestible carbohydrates as
energy sources, encompassing plant-derived carbohydrates [such
as resistant starch, pectin, inulin, arabinoxylan (AX), cellulose,
and their corresponding oligosaccharides] and host-produced
carbohydrates (human milk oligosaccharides and mucin),
although this ability is strain-dependent too (Klijn et al., 2005;
De Vuyst et al., 2014; Rivière et al., 2014; McLaughlin et al., 2015;
Selak et al., 2016).
Once internalized into the cytoplasm, hexose
monosaccharides (e.g., fructose and glucose) are converted into
acetate and lactate by the fructose 6-phosphate phosphoketolase
pathway or bifid shunt (De Vuyst et al., 2014). Bifidobacteria
will initially cleave, by means of the key enzyme fructose
6-phosphate phosphoketolase, one mole of fructose 6-phosphate
into one mole of erythrose 4-phosphate and one mole of
acetyl-phosphate (Figure 2A). From erythrose 4-phosphate
and an additional mole of fructose 6-phosphate, one mole
of ribose 5-phosphate and one mole of xylulose 5-phosphate
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FIGURE 2 | (A) Schematic representation of the fermentation of hexoses (glucose and fructose) and pentoses (arabinose and xylose) by bifidobacteria through the
fructose 6-phosphate phosphoketolase pathway or bifid shunt. (B) Schematic representation of the fermentation of hexoses (glucose and fructose) and pentoses
(arabinose and xylose) by butyrate-producing colon bacteria through the Embden-Meyerhof-Parnas pathway and pentose-phosphate pathway, respectively, and of
lactate. Dashed lines represent different steps. Underlined metabolites are excreted into the extracellular medium. Fdox, oxidized ferredoxin; Fdred, reduced
ferredoxin; FAD, flavin adenine dinucleotide; enzymes: 1, fructose 6-phosphate phosphoketolase; 2, transaldolase; 3, transketolase; 4, xylulose 5-phosphate
phosphoketolase; 5, acetate kinase; 6, lactate dehydrogenase; 7, formate acetyltransferase; 8, bifunctional aldehyde-alcohol dehydrogenase; 9,
phosphotransacetylase; 10, phosphoenolpyruvate carboxylase; 11, malate dehydrogenase; 12, fumarase; 13, succinate dehydrogenase; 14, pyruvate:ferredoxin
oxidoreductase; 15, pyruvate-formate lyase; 16, butyryl-CoA dehydrogenase/electron-transferring flavoprotein (Bcd/Etf) complex; 17, butyrate kinase; 18,
butyryl-CoA:acetate CoA transferase; 19, ferredoxin hydrogenase; and 20, membrane-bound ferredoxin oxidoreductase (Rnf) complex.
are formed by the successive action of a transaldolase and
a transketolase. Two moles of xylulose 5-phosphate are
subsequently converted into two moles of acetyl-phosphate
and two moles of glyceraldehyde 3-phosphate by the action of
a xylulose 5-phosphate phosphoketolase. These two moles of
acetyl-phosphate plus the additional mole of acetyl-phosphate
(produced by the fructose 6-phosphate phosphoketolase) are
further converted into three moles of acetate by an acetate
kinase, which is accompanied by the production of three moles
of ATP. The two moles of glyceraldehyde 3-phosphate are
oxidized into two moles of pyruvate by enzymes participating
in the Embden-Meyerhof-Parnas pathway, which results in
an additional production of two moles of ATP. In a last step,
pyruvate can be reduced into lactate by means of a lactate
dehydrogenase, which is accompanied by NAD+ recycling.
Thus, when fermenting hexose monosaccharides, acetate and
lactate are produced in a theoretical molar ratio of 1.5 and three
moles of ATP are produced. Pentose monosaccharides (e.g.,
arabinose and xylose) can also be shuttled into the bifid shunt
by their conversion into xylulose 5-phosphate (Figure 2A).
However, this is not accompanied by the production of an
additional mole of acetate (and thus no additional mole of
ATP) as in the case of hexose fermentation, leading to a final
theoretical molar ratio of acetate to lactate of 1.0 and two
moles of ATP (Pokusaeva et al., 2011; De Vuyst et al., 2014).
However, these theoretical ratios are rarely found during
bifidobacterial carbohydrate fermentation, due to the production
of formate, acetate, and ethanol from pyruvate instead of lactate
(Figure 2A), which depends on the available energy source
and its consumption rate (Palframan et al., 2003; Van der
Meulen et al., 2004, 2006a,b; Falony et al., 2009b; De Vuyst
et al., 2014). The production of formate from pyruvate by
a formate acetyltransferase, at the expense of lactate, can be
explained by the need for additional ATP production by means
of the concomitant production of acetate when bifidobacteria are
grown on complex carbohydrates to improve their fitness, despite
their lower growth rate compared with simple carbohydrates.
Bifidobacteria are also able to produce ethanol from acetyl-CoA
with a bifunctional aldehyde-alcohol dehydrogenase, at the
expense of acetate, to enable the continuation of pyruvate
production by regenerating NAD+. This shift in metabolism
away from lactate production has been found for the degradation
of complex carbohydrates such as inulin-type fructans (ITF;
oligofructose and inulin; Van der Meulen et al., 2004; Falony
et al., 2009b) and arabinoxylan-oligosaccharides (AXOS; Rivière
et al., 2014, 2015). Bifidobacteria can also regenerate NAD+ by
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the production of succinate from oxaloacetate that is in turn
formed from phosphoenolpyruvate (Figure 2A; Van der Meulen
et al., 2006a).
Butyrate-Producing Colon Bacterial
Species
General Aspects
Gene-targeted approaches to investigate the butyrate-producing
bacterial communities of the human gut microbiota have led
to the consideration that butyrate-producing colon bacteria
form a functional group rather than a monophyletic group.
Most butyrate producers in the human colon belong to the
Firmicutes phylum and in particular clostridial clusters IV and
XIVa (Louis and Flint, 2009; Van den Abbeele et al., 2013a; Vital
et al., 2014). Clostridial clusters IV and XIVa butyrate producers
are Gram-positive, highly oxygen-sensitive, strictly anaerobic,
saccharolytic bacteria. The two most dominant bacterial species
in the human colon are Faecalibacterium prausnitzii (up to
14% of the total fecal gut microbiota, clostridial cluster IV)
and Eubacterium rectale (up to 13% of the total fecal gut
microbiota, clostridial cluster XIVa), and are expected to have
a significant contribution to butyrate production (De Vuyst
et al., 2014; Walker et al., 2014). Other important butyrate-
producing bacterial species in the human colon are Roseburia
spp. (clostridial cluster XIVa, such as Roseburia faecis, Roseburia
inulinivorans, Roseburia intestinalis, and Roseburia hominis),
Eubacterium spp. (clostridial cluster XIVa, such as Eubacterium
hallii), Anaerostipes spp. (clostridial cluster XIVa, such as
Anaerostipes butyraticus, Anaerostipes caccae, and Anaerostipes
hadrus), and Butyricicoccus pullicaecorum (clostridial cluster
IV). Some of these species (such as E. rectale, F. prausnitzii,
and R. intestinalis) preferentially colonize the mucus layer,
and consequently increase the butyrate bioavailability for colon
epithelial cells, whereas other species such as A. caccae mainly
occur in the lumen of the colon (El Aidy et al., 2013; Van den
Abbeele et al., 2013a). In contrast to bifidobacteria, clostridial
clusters IV and XIVa do not directly colonize the colon in high
quantities after birth. In the case of F. prausnitzii, it has been
shown that fecal numbers in infants younger than 6 months
are undetectable, slightly increase between the age of 6 and 24
months, then suddenly increase to reach a peak during late
childhood and adolescence, and finally decrease again during
adulthood and especially in the elderly (Miquel et al., 2014).
Functional Role in the Colon
Clostridial clusters IV and XIVa have gained a lot of
attention during the last years because of their contribution
to gut homeostasis, by preserving gut barrier functions and
exerting immunomodulatory and anti-inflammatory properties
(Velasquez-Manoff, 2015). In addition to the beneficial properties
of the butyrate produced (Table 1), F. prausnitzii produces anti-
inflammatory peptides blocking nuclear factor NF-κB activation
and cytokine IL-8 production in mice, which provide protection
against chemically induced colitis (Qiu et al., 2013; Quévrain
et al., 2016). Several studies have shown that the abundance of
B. pullicaecorum, E. rectale, F. prausnitzii, and/or R. intestinalis
is markedly decreased in IBD patients (Morgan et al., 2012;
Eeckhaut et al., 2013; Gevers et al., 2014) and that such
patients have lower concentrations of butyrate in their feces
than healthy individuals (Marchesi et al., 2007; Nemoto et al.,
2012). Less butyrate producers were also found in patients with
colorectal cancer (Wu et al., 2013). Therefore, methods are being
searched to stimulate butyrate-producing human colon bacterial
species by diet (prebiotic approach) or by administering these
bacteria orally (probiotic approach). In medical applications,
pure butyrate by means of tablets or rectal enemas is used as a
therapeutic agent for IBD treatment (Geirnaert et al., 2014).
Metabolism
Like bifidobacteria, members of clostridial clusters IV and XIVa
carry out a fermentative metabolism and are often able to
degrade a wide range of non-digestible carbohydrates in the
human colon anaerobically, encompassing resistant starch, ITF,
xylo-oligosaccharides (XOS), and AXOS (Falony et al., 2009c;
Louis and Flint, 2009; Scott et al., 2014; Rivière et al., 2015;
Moens et al., 2016). As an example, the genome of E. rectale
ATCC 33656 encodes 52 glycoside hydrolases, encompassing β-
fructofuranosidases, α-arabinofuranosidases, β-xylosidases, exo-
oligoxylanases, α-amylases, α- and β-glucosidases, α- and β-
galactosidases, and cellulases (Lombard et al., 2014). However,
inter-genus variations have been found within clostridial
clusters IV and XIVa, as not all species and even strains
within one species can consume complex carbohydrates
to the same extent (Falony et al., 2009c; Scott et al.,
2014; Moens et al., 2016). Most of the butyrate-producing
colon bacteria use a non-preferential extracellular degradation
mechanism for the breakdown of oligo- and polysaccharides,
with the release of monosaccharides into the extracellular
medium. As illustrated during laboratory batch fermentation
experiments, co-cultivation of such butyrate-producing bacteria
with bifidobacteria that have a preferential carbohydrate
degradationmechanism, can comprise the competitiveness of the
butyrate-producing colon bacteria (Falony et al., 2006, 2009c; De
Vuyst et al., 2014). For instance, the percentage of oligofructose
that was consumed by F. prausnitzii DSM 17677T when co-
cultivated with different bifidobacterial strains decreased with an
increasing ITF degradation capacity of the latter (Moens et al.,
2016).
Once internalized into the cytoplasm, hexoses and pentoses
are degraded to pyruvate by the Embden-Meyerhof-Parnas
pathway or pentose phosphate pathway, respectively. Like
other fermentative bacteria, clostridial clusters IV and XIVa
butyrate producers possess several alternative pathways to form
different end-metabolites from pyruvate, depending on the
bacterial species, carbohydrate source, hydrogen gas pressure,
and necessity of redox balancing. Besides butyrate, they can form
lactate, formate, hydrogen gas, and carbon dioxide (Figure 2B).
Pyruvate can get reduced into lactate by means of a lactate
dehydrogenase, which is accompanied by NAD+ recycling (for
instance R. inulinivorans and E. rectale; Falony et al., 2009c;
Rivière et al., 2015; Moens et al., 2016). The production of
butyrate from pyruvate involves the conversion of pyruvate
into acetyl-CoA by a pyruvate:ferredoxin oxidoreductase, with
the reduction of ferredoxin and production of carbon dioxide
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(for instance most clostridial clusters IV and XIVa butyrate-
producing colon bacteria; Falony et al., 2009c; Moens et al.,
2016) and/or by a pyruvate-formate lyase with the formation
of formate (for instance F. prausnitzii and E. rectale; Rivière
et al., 2015; Moens et al., 2016). Two moles of acetyl-CoA
are then converted via a four-step pathway into butyryl-
CoA, in which the last step is carried out by a butyryl-CoA
dehydrogenase/electron-transferring flavoprotein complex that
catalyzes the NADH + H+-dependent reduction of crotonyl-
CoA coupled to the reduction of ferredoxin. The final step from
butyryl-CoA to butyrate is either catalyzed by a butyrate kinase
(after phosphorylation of butyryl-CoA) or a butyryl-CoA:acetate
CoA transferase (Falony et al., 2009c; Louis and Flint, 2009;
Mahowald et al., 2009; De Vuyst and Leroy, 2011; Moens
et al., 2016). Only a few butyrate-producing colon bacteria,
encompassing Clostridium butyricum, Coprococcus eutactus, and
Coprococcus comes, are known to use a butyrate kinase to
produce butyrate (Louis and Flint, 2009; Vital et al., 2014).
The butyryl-CoA:acetate CoA transferase step involves the
consumption of external acetate (coming from for instance
bifidobacterial carbohydrate breakdown through cross-feeding)
as a co-substrate, thereby producing acetyl-CoA and butyrate.
The acetyl-CoA produced can be converted via acetyl-phosphate
into acetate, with the production of ATP, by acetate kinase, or
recycled into the four-step pathway mentioned above (Falony
et al., 2009c). The reduced ferredoxin can be reoxidized via a
ferredoxin hydrogenase, with the concomitant production of H2,
and/or via a membrane-bound ferredoxin oxidoreductase (Rnf)
complex, without production of H2, but with the generation of a
proton-motive force that allows additional ATP production (for
instance R. inulinivorans and F. prausnitzii; Falony et al., 2009c;
Moens et al., 2016). The production of butyrate thus not only
leads to regeneration of NAD+ from NADH + H+ produced
in the upper parts of the carbohydrate degradation pathways for
ATP production, but also leads to additional ATP production
(Falony et al., 2009c; Louis and Flint, 2009; Mahowald et al.,
2009; De Vuyst and Leroy, 2011). Some butyrate producers,
encompassing A. caccae, A. butyraticus, A. hadrus, and E. hallii,
can produce butyrate from lactate instead of carbohydrates
(Figure 2B; Duncan et al., 2004; Falony et al., 2006, 2009c;
Belenguer et al., 2011; De Vuyst and Leroy, 2011; De Vuyst et al.,
2014).
STIMULATION OF BIFIDOBACTERIA AND
BUTYRATE-PRODUCING COLON
BACTERIA
Since decreased numbers of Bifidobacterium species and
butyrate-producing bacterial species in the human colon have
been reported in patients with diverse disorders and because
the SCFAs produced by these species have beneficial effects
(Table 1), these bacteria are potential candidates to be stimulated
in the colon to prevent and restore a disturbed gut homeostasis.
The most prevalent strategies to stimulate bifidobacteria and
butyrate-producing colon bacteria in the human colon involve
the consumption of probiotics and prebiotics (Scott et al., 2015).
Probiotics
According to the international scientific association for
probiotics and prebiotics (ISAPP), probiotics are defined as “live
microorganisms that, when administered in adequate amounts,
confer a health benefit on the host” (Hill et al., 2014). Selected
strains of Bifidobacterium species are commonly used probiotics
and are added to food supplements and foods (especially
dairy products). The oral consumption of bifidobacteria has
been associated with beneficial effects for different digestive
problems and disorders, encompassing acceleration of the gut
transit time; improvement of lactose intolerance; prevention
of antibiotic-associated diarrhea and necrotizing enterocolitis
(in pre-term infants that usually harbor reduced numbers
of bifidobacteria); and alleviation of IBS and IBD symptoms
(Leahy et al., 2005; Di Gioia et al., 2014; Tojo et al., 2014;
Saez-Lara et al., 2015). Also, evidence continues to emerge
that bifidobacteria influence immune responses and hence may
enhance resistance to infections and allergies (Di Gioia et al.,
2014; Frei et al., 2015). Further, bifidobacteria display anti-
inflammatory effects and negatively correlate with metabolic
endotoxemia (Everard and Cani, 2013). Moreover, interest is
growing to use bifidobacterial strains (such as Bifidobacterium
infantis 35624) as psychobiotics, which are “live organisms
that, when ingested in adequate amounts, produce a health
benefit in patients suffering from psychiatric illness” (Dinan
et al., 2013, 2015). The health effects that bifidobacteria exert
are of course strain-related; some bifidobacterial strains are
effective, whereas others are not. Moreover, the probiotic health
benefits are probably not caused by the bifidobacterial strains
consumed solely, but are rather the result of interactions with
the resident gut microbiota (Cani and Van Hul, 2015; Scott et al.,
2015). Indeed, a recent metagenomic and metatranscriptomic
study of feces of 12 healthy individuals has shown that the oral
administration of the probiotic strain Lactobacillus rhamnosus
GG significantly changes the activity of the resident gut
microbiota, without influencing the gut microbiota composition
itself (Eloe-Fadrosh et al., 2015). Especially genes involved in
adhesion, chemotaxis, and/or motility of Bifidobacterium spp.,
Eubacterium spp., and Roseburia spp. are overexpressed during
probiotic consumption, suggesting that the consumption of
the probiotic strain promotes interactions between the resident
gut microbiota and the host. Nowadays, there is also a growing
interest toward the use of other bacterial strains as probiotics,
such as Akkermansia muciniphila and butyrate-producing
colon bacteria, encompassing B. pullicaecorum, E. rectale,
F. prausnitzii, and Roseburia spp. (Marteau, 2013; Geirnaert
et al., 2014; Cani and Van Hul, 2015; Scott et al., 2015). For
example, the oral administration of B. pullicaecorum 25-3T
and F. prausnitzii A2-165 in rodents has shown attenuation of
chemically induced colitis (Eeckhaut et al., 2013, 2014; Martín
et al., 2015). However, whether these strict anaerobic colon
bacteria can survive the harsh industrial production steps and
deal with the regulatory hurdles (as these bacteria have no
history of safe use) will partly determine their application as
probiotics in the future human diet (Figueroa-González et al.,
2011; Gosálbez and Ramón, 2015; Kumar et al., 2015; Scott et al.,
2015).
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Since the implementation of EU legislation on health claims in
2009, no health claims for probiotics in foods have been approved
by the European Food Safety Authority (EFSA) neither can the
term probiotic further be used as a food label in Europe (Glanville
et al., 2015). The only approved health claim is the benefit on
lactose digestion when consuming live Lactobacillus delbrueckii
subsp. bulgaricus and Streptococcus thermophilus strains present
in yogurt or fermented milk (EFSA, 2010).
In severe cases of a disturbed gut homeostasis, whereby
probiotic treatments do not suffice, the gut microbiota can
be restored by transplanting the complete fecal microbiota
from a healthy donor into a diseased person. However,
the ISAPP recommends that fecal microbiota transplantations
(FMTs) should not be considered as probiotics, as they are
uncharacterized mixtures of strains (Hill et al., 2014). FMTs
have shown to be very effective for curing Clostridium difficile
infections, although they have ambiguous outcomes for IBD and
IBS (Aroniadis and Brandt, 2014; Pamer, 2014). Furthermore, a
step-up FMT strategy has been proposed to treat Crohn’s disease
and ulcerative colitis, which consists of a FMT, followed by
additional FMT steps or standard IBD medications depending
on the patient’s clinical response to the treatment (Cui et al.,
2016). Also, it has been shown that patients with metabolic
syndrome display improved insulin sensitivity after being treated
with fecal microbiota of healthy individuals (Vrieze et al., 2012).
These patients possess increased numbers of butyrate-producing
colon bacteria and decreased numbers of Gram-negative bacteria
after a FMT. Studies are being performed to see whether FMTs
can also cure non-gastrointestinal disorders, such as allergies
and behavioral disorders (Xu et al., 2015). However, up to
now, few fecal transplants have been performed, as the selection
of healthy fecal donors requires a thorough examination to
avoid the transfer of pathogens and gut microbiota-associated
disorders (Kapel et al., 2014). Therefore, new approaches are
being searched to transplant well-defined mixtures of bacteria
(de Vos, 2013; Van den Abbeele et al., 2013b). However, an
additional challenge in selecting an appropriate healthy donor or
bacterial synthetic community is that, despite the large amount
of information about the composition and diversity of the human
gut microbiota, it is difficult (if not impossible) to define a healthy
gut microbiota composition, as each healthy individual harbors
a unique gut microbiota (de Vos and de Vos, 2012; Faith et al.,
2013; Li et al., 2016).
Prebiotics
General
Another strategy to increase bifidobacteria and butyrate-
producing bacteria in the human colon is through the
consumption of prebiotics, which are defined according to
the ISAPP as “a selectively fermented ingredient that results
in specific changes in the composition and/or activity of the
gastrointestinal microbiota, thus conferring benefit(s) upon host
health” (Gibson et al., 2010). To date, all well-known prebiotics
are carbohydrates, although other compounds such as, for
instance, polyphenols may display prebiotic properties as well
(Bindels et al., 2015). Compared with probiotics, prebiotics are
more stable and thus can easily be added to foods, such as
yogurts, biscuits, breads, cereals, spreads, ice creams, and drinks
(Gibson et al., 2010). The criteria for classifying a compound as
a prebiotic have been listed as (i) resistance to gastric acidity,
hydrolysis bymammalian digestive enzymes, and gastrointestinal
absorption; (ii) fermentation by intestinal microbiota; and (iii)
selective stimulation of the growth and/or activity of intestinal
bacteria associated with health and well-being (Gibson et al.,
2004). In the past, the impact of the consumption of prebiotics
on the gut microbiota composition was mainly studied regarding
species of Bifidobacterium and Lactobacillus (Verbeke, 2014).
However, recent community-wide analyses of the gut microbiota
show that prebiotics are not that selective as previously assumed,
and that they stimulate other bacteria too (Bindels et al., 2015). It
has indeed been shown that butyrate-producing colon bacteria,
such as E. rectale, F. prausnitzii, and Roseburia spp., can consume
prebiotics such as ITF (Falony et al., 2006, 2009c; Rivière et al.,
2015; Moens et al., 2016). Also, the consumption of oligofructose
changes the relative abundance of 102 bacterial taxa in mice, of
which 16 display a more than 10-fold decrease or increase in
abundance (Everard et al., 2011). Therefore, Bindels et al. (2015)
proposed to define a prebiotic as “a non-digestible compound
that, through its metabolization by microorganisms in the gut,
modulates composition and/or activity of the gut microbiota,
thus conferring a beneficial physiological effect on the host.”
Alternatively, the definition of prebiotics has been challenged
over time not only according to scientific considerations but also
due to its importance for regulators, industry, and consumers
(Hutkins et al., 2016). As for probiotics, the term prebiotic cannot
be used as a health claim on food products in Europe (Salminen
and van Loveren, 2012). Some claims exist for the term fiber
(EFSA, 2011a,b, 2015), but not all fibers are prebiotics, whereby
the latter are distinguished from the former by the selectivity of
their fermentation (Slavin, 2013; Hutkins et al., 2016; Verspreet
et al., 2016).
Examples of prebiotic non-digestible carbohydrates that
are bifidogenic include poly- and oligosaccharides containing
fructose (and a terminal glucose) as in ITF, galactose and
glucose (as in galacto-oligosaccharides), glucose (as in isomalto-
oligosaccharides), galactose and fructose (as in lactulose), xylose
(as in XOS), and arabinose and xylose (as in AX and AXOS)
(Roberfroid, 2005; Macfarlane et al., 2008; Broekaert et al., 2011;
De Vuyst and Leroy, 2011; De Vuyst et al., 2014). Whereas,
in the past the target genus for prebiotic stimulation was
Bifidobacterium (Gibson et al., 2010), today new prebiotics are
searched to stimulate other beneficial bacterial species in the
human colon such as butyrate producers. Of special interest are
prebiotics that cause both a bifidogenic effect and a butyrogenic
effect. ITF, AX, and AXOS are such prebiotics that stimulate both
bifidobacteria and the production of butyrate (Falony et al., 2006,
2009b,c; De Vuyst and Leroy, 2011; De Vuyst et al., 2014; Rivière
et al., 2015).
ITF As an Example of Well-Known Prebiotics
Inulin naturally occurs in fruits and plants such as chicory
roots, wheat, onion, banana, garlic, and leek, but is generally
extracted from chicory roots on an industrial scale (Roberfroid,
2007). Inulin consists of a linear backbone of β-(2→1)-linked
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fructose monomers with a degree of polymerization (DP)
between 2 and 65 (average DP of 10), which is often linked
to a terminal glucose monomer by an α-(1→2)-glycosidic
bond (Figures 3A,B). Oligofructose is derived from native
inulin by partial enzymatic hydrolysis with an inulinase and
has a DP that varies between 2 and 8 (average DP of 4).
Given the relative simple structures of ITF, only few bacterial
enzymes are required for their degradation in the human colon,
encompassing enzymes belonging to the β-fructofuranosidase
(EC 3.2.1.26) superfamily that cleave terminal fructose residues
from the non-reducing ends of the fructose polymers (Figure 3B;
Scott et al., 2011). Several β-fructofuranosidases have been
isolated and characterized in colon bacteria, for instance in
Bifidobacterium species (Warchol et al., 2002; Ehrmann et al.,
2003; Omori et al., 2010; Jedrzejczak-Krzepkowska et al., 2011)
and R. inulinivorans (Scott et al., 2011). Examples of beneficial
effects of the consumption of ITF include increased stool
frequency, increased colonic absorption of dietary minerals
(calcium and magnesium), decreased proteolytic activity, and
increased secretion of satiety hormones (Schaafsma and Slavin,
2015).
ITF belong to themost studied prebiotics and their bifidogenic
and butyrogenic effects have been well established in various
studies (De Vuyst and Leroy, 2011; De Vuyst et al., 2014).
For instance, it has been shown that not all bifidobacterial
strains benefit in the same way from the presence of ITF
in the human colon. A comparative statistical study of 18
bifidobacterial strains, belonging to 10 different species and
FIGURE 3 | Chemical structures [(A) and (C)] and schematic representations [(B) and (D)] of ITF, AX, and AXOS molecules. Glc, glucose; Fru, fructose; Xyl,
xylose; Ara, arabinose; FeA, ferulic acid; Ac, acetyl group; GlA, glucuronic acid; CouA, p-coumaric acid. Arrows indicate possible hydrolysis of the carbohydrates by
bacterial enzymes present in the human colon: 1, β-fructofuranosidase; 2, β-xylosidase; 3, β-endoxylanase; 4, exo-oligoxylanase; 5, α-arabinofuranosidase; 6,
α-glucuronidase; and 7, esterase.
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coming from different donors and origins, has shown the
existence of four different clusters of strains differing in their
mechanisms and capabilities to degrade ITF (Falony et al.,
2009b). Some strains only consume fructose (cluster A), whereas
others consume both fructose and oligofructose, mainly short
oligosaccharides (DP up to seven) after import into the cell,
i.e., they display a preferential metabolism (cluster B). Certain
strains degrade both oligofructose and inulin (short chain length
fractions only) extracellularly, accompanied with the release of
fructose into the extracellular medium, i.e., they display a non-
preferential metabolism (clusters C and D). A recent study of 190
bifidobacterial strains isolated from different donors and colon
regions has shown that these ITF degradation fingerprints are
not correlated with the region in the intestine, suggesting that the
degradation of ITF is uniform along the human intestine (Selak
et al., 2016). Yet, intra-species variability in ITF degradation
capacity indicates strain-specific variations. Moreover, within
one colon region bifidobacterial strains with different ITF
degradation mechanisms occur, which suggests cooperation
for the degradation of ITF in the colon, with opportunities
for cross-feeding on strain and/or species level. Similar cross-
feeding between bifidobacterial strains with complementary
degradation mechanisms has also been shown for starch,
xylan, and mucin glycoproteins (Egan et al., 2014; Turroni
et al., 2015). Also, it has been shown that the consumption
of ITF, the bifidogenic effect, and the butyrogenic effect are
linked to each other, because of cross-feeding interactions
between bifidobacteria and butyrate-producing colon bacteria
(Figure 4; Belenguer et al., 2006; Falony et al., 2006, 2009c;
Moens et al., 2016). As an end-metabolite of the bifid shunt
and a co-substrate for the production of butyrate (Section
AX and AXOS as an Example of Interesting Prebiotics),
acetate plays a key role in cross-feeding interactions between
bifidobacteria and butyrate-producing colon bacteria in the
human colon. In a first type of cross-feeding, both the
bifidobacterial and butyrate-producing strains consume ITF
(Figure 4). The consumption of ITF by bifidobacteria provides
butyrate-producing colon bacteria with exogenous acetate that
is used as a co-substrate to produce butyrate by growing on
ITF simultaneously [which is, for instance, the case for R.
intestinalis DSM 14610 (Falony et al., 2006), R. inulinivorans
DSM 16841 (Falony et al., 2009c), and F. prausnitzii DSM
17677T (Moens et al., 2016)]. However, such cross-feeding
interactions can be either a pure commensal or beneficial
relationship between these bacteria or can be dominated by
competition, depending on the ITF degradation capacities of
the bifidobacterial strains involved (Moens et al., 2016). A
second type of cross-feeding takes place between bifidobacteria
that consume ITF, and concomitantly produce acetate, and
acetate-consuming butyrate-producing colon bacteria that are
not able to degrade ITF (Figure 4). Instead of ITF, the latter
bacteria consume carbohydrate breakdown products (short-
chain oligosaccharides) liberated by the bifidobacterial strain
(which is, for instance, the case for R. hominis DSM 16839;
Belenguer et al., 2006) or lactate (for instance E. hallii DSM
17630; Belenguer et al., 2006, and A. caccae DSM 14662; Falony
et al., 2006).
AX and AXOS As an Example of Interesting Prebiotics
Physiological effects
Growing interest is devoted to complex non-digestible
carbohydrates that ferment slowly and thereby cause bifidogenic
and butyrogenic effects along the entire length of the human
colon. AX and AXOS, as a broad class of heteropolysaccharides
and -oligosaccharides with complex varying structures
(Figures 3C,D), belong to these slow-fermenting carbohydrates
and hence are able to decrease the production of bacterial toxic
metabolites originating from protein and lipid metabolism
in the distal colon (Section Bifidobacterium Species; Van
Craeyveld et al., 2008; Grootaert et al., 2009; Sanchez et al., 2009;
Neyrinck et al., 2011). This is to be explained by a stimulation
of saccharolytic activities, an increase in SCFA production, and
a lowering of the luminal pH in the distal part of the colon,
where carbohydrates are rare and proteolytic bacteria, such as
Bacteroides spp., are otherwise favored (Duncan et al., 2009).
Examples of additional potential benefits of the consumption
of AX and AXOS for human health include improved mineral
(calcium and magnesium) absorption; increased stool frequency
and improved stool consistency; reduced post-prandial glycemic
response; reduced blood cholesterol levels; and increased
antioxidant capacity (Grootaert et al., 2007; Broekaert et al.,
2011; Damen et al., 2011; Mendis and Simsek, 2013). Moreover,
the consumption of AXOS, with the increase of bifidobacterial
numbers as a result, may help to restore gut barrier functions
and cure metabolic endotoxemia in mice (Neyrinck et al.,
2012).
Occurrence, structural properties, and degradation
AX naturally occur in the endosperm and bran (pericarp, testa,
and aleuron layer) of cereal grains such as wheat, rye, rice,
barley, oat, and sorghum, but in varying quantities, depending
on the cereal species and the location within the cereal kernel
(Izydorczyk and Biliaderis, 2006). For instance, the endosperm
of wheat kernels contains ca. 2% of AX, whereas the pericarp
contains ca. 38% of AX (Benamrouche et al., 2002; Maes and
Delcour, 2002). AX consist of a linear backbone of 1500 to 15,000
β-(1→4)-linked xylose monomers, which can randomly be
substituted with arabinose monomers on the C-(O)-2 or C-(O)-3
positions (monosubstituted) or on both positions (disubstituted;
Figures 3C,D; Izydorczyk and Biliaderis, 1995). Distribution
patterns of arabinose substituents on the xylose backbone are not
regular for wheat AX; highly branched regions are interlinked
by sequences of contiguous non-substituted xylose residues
(Gruppen et al., 1993). The number of arabinose substituents
bound to the xylose backbone is expressed as the arabinose/xylose
ratio (A/X) and depends on the cereal species and the location
within the kernel. For instance, in the pericarp, testa, aleuron
layer, and endosperm of wheat kernels, different A/Xs are found,
namely ca. 1.0, 0.1, 0.4, and 0.5, respectively (Izydorczyk and
Biliaderis, 1995; Antoine et al., 2003; Barron et al., 2007).
The fermentability of AX and AXOS in the human colon is
strongly influenced by the complexity of the AXOS molecules
and decreases with increasing DP and increasing A/X (Van
Craeyveld et al., 2008; Pollet et al., 2012). Additionally, xylose
residues can be esterified with glucuronic acid and acetyl groups,
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FIGURE 4 | Different types of cross-feeding that can take place between Bifidobacterium spp. and species of butyrate-producing colon bacteria in the
human colon. Arrows indicate consumption of oligofructose, inulin, and AXOS (.....), production of carbohydrate breakdown products and/or metabolic
end-products (- - -), and cross-feeding interactions between the bifidobacterial and butyrate-producing strains (—).
whereas arabinose residues can be esterified with ferulic acid
and p-coumaric acid, although in low numbers (Figure 3D;
Izydorczyk and Biliaderis, 1995). These esterifications are of
health and physicochemical importance, since ferulic acid and
p-coumaric acid are antioxidants and potent cross-linking sites
for attachment to other AX chains (Bunzel et al., 2001; Ou
and Sun, 2014). The presence of feruloylated and diferuloylated
arabinose substituents reduces the fermentability of AX and
AXOS (Hopkins et al., 2003; Snelders et al., 2014). As cereal whole
grains only contain low concentrations of AX (varying between
1.8% of AX in sorghum and 12.1% of AX in rye; Izydorczyk
and Biliaderis, 2006), and thus the overall intake of AX is low
(especially in modern Western-type diets with high intakes of
refined cereal products), AX can be extracted from cereal grains
and added to food products in higher concentrations (Broekaert
et al., 2009). On an industrial scale, AX are usually extracted
from wheat bran that is available in large quantities in Europe
(Swennen et al., 2006). AXOS, the hydrolysis products of AX, are
formed not only in processed cereal-based food products such
as bread and beer (Courtin et al., 2009; Broekaert et al., 2011),
but can also be produced on an industrial scale by the enzymatic
cleavage of AX with β-endoxylanases (Broekaert et al., 2009,
2011). This results in various substituted molecules (i.e., AXOS)
and non-substituted molecules (i.e., XOS), differing in DP and
A/X.
Given their complex structures, the degradation of AX and
AXOS in the human colon requires the cooperative action of
debranching and depolymerizing bacterial carbohydrate-active
enzymes, encompassing β-endoxylanases (EC 3.2.1.8) that cleave
AX into AXOS and XOS; β-xylosidases (EC 3.2.1.37) that
cleave terminal xylose residues from the non-reducing ends of
the xylose backbones; exo-oligoxylanases (EC 3.2.1.156) that
release terminal xylose residues from the reducing ends of
the xylose backbones; and α-arabinofuranosidases (EC 3.2.1.55)
that remove arabinose substituents from the xylose backbones
(Figure 3D). Additional enzymes are needed to cleave glucuronic
acid [i.e., α-glucuronidase (EC 3.2.1.139)], ferulic acid [i.e.,
ferulic acid esterase (EC 3.1.1.73)], acetyl groups [i.e., acetyl xylan
esterase (EC 3.1.1.72)], and p-coumaric acid [i.e., p-coumaric acid
esterase (EC 3.1.1.-)] from AXOS (Figure 3D; Dodd and Cann,
2009; Lagaert et al., 2014).
To date, AX and AXOS fall under the definition of dietary
fiber (European Commission, 2008; Snelders et al., 2014) but
are not considered as prebiotics by the EFSA, although they
meet the three criteria of prebiotics (see above; Broekaert et al.,
2011). AX and AXOS are neither digested nor absorbed in the
upper gastrointestinal tract and reach the human colon intact,
where they are fermented by the resident colon bacteria and
cause bifidogenic and butyrogenic effects (Table 2). However,
as is also the case for other prebiotics, the selective stimulation
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criterion can be questioned. Several in vivo and in vitro studies
have shown that AX and AXOS stimulate, besides bifidobacteria
and butyrate-producing colon bacteria, other saccharolytic colon
bacteria too, such as Bacteroides spp. and Lactobacillus spp.
(Table 2). Moreover, a propionogenic effect is supposed to occur.
A few studies have shown that AX and AXOS especially stimulate
the production of propionate (Table 2; Hopkins et al., 2003;
Van den Abbeele et al., 2011; Pollet et al., 2012). For instance,
the mucin-consuming propionate-producing A. muciniphila is
stimulated in the colon of humanized rats fed with long-chain AX
(Table 2; Van den Abbeele et al., 2011). Whether this is a direct or
indirect effect is not known yet.
Bifidogenic effects of AX and AXOS
Several in vivo studies (in rodents, pigs, and humans) and
in vitro studies [during batch and simulator of human
intestinal microbial ecosystem (SHIME R©) fermentations with
fecal slurries] have shown that AX and AXOS are bifidogenic
(Table 2). An in vivo study with rats has shown that the
bifidogenic effect is only caused by AXOS with low average
DPs ≤ 5 and A/Xs ≤ 0.27 (Van Craeyveld et al., 2008), whereas
other rodent studies have found a stimulation of bifidobacteria
by AX and AXOS with high average DPs up to 284 and A/Xs
up to 0.70 (Table 2; Damen et al., 2011; Neyrinck et al., 2011;
Van den Abbeele et al., 2011). In the latter study, a 60-fold
increase of bifidobacteria in the cecum of rats has been found,
caused by the consumption of long-chain AX (average DP of
60, A/X of 0.70; Van den Abbeele et al., 2011). Apart from
in vitro and animal experiments, human studies have revealed
a bifidogenic effect caused by a daily intake of 10 g of AXOS
per day (Cloetens et al., 2010), 5.5 g of AXOS per day (Maki
et al., 2012), and 2.2 g of AX and AXOS per day (Walton
et al., 2012; Table 2). However, until recently, many fundamental
questions remain unanswered. For instance, how can the low
numerical abundant bifidobacteria (<5%) compete with other,
more abundant, saccharolytic bacteria in the human colon for
AX and AXOS? Do bifidobacteria have a preference for certain
AX and AXOS molecules? Are all bifidobacterial strains in
the human colon stimulated by AX and AXOS? To answer
these questions, a detailed knowledge of the carbohydrate-
hydrolyzing capacity of bifidobacteria was missing. Indeed, in
the past, studies of the degradation of AX and AXOS through
mono-culture fermentations with bifidobacterial strains were
restricted to monitoring of bacterial growth, pH, and SCFA
production (Van Laere et al., 2000; Crittenden et al., 2002),
or fermentations of purified short-chain AXOS standards were
performed (Pastell et al., 2009) without revealing the complete
fermentation capacity of bifidobacteria. Recently, themechanistic
variations in AXOS degradation by 36 bifidobacterial strains
from different donors and origins have been investigated (Rivière
et al., 2014). The results show that not all bifidobacterial
strains are stimulated by AXOS to the same extent. AXOS
degradation by bifidobacteria is complex and involves the
consumption of arabinose substituents, whether or not followed
by the consumption of the xylose backbones of AXOS, either
up to xylotetraose or longer and either intracellularly or
extracellularly. Several bifidobacterial strains use the arabinose
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substituents of AXOS solely, whereas others first consume the
arabinose substituents and later import the xylose backbones
(up to xylotetraose) into the cell. This extracellular arabinose
substituent-oriented metabolism of bifidobacteria has been
linked to the presence of genes encoding extracellular cell-
associated α-arabinofuranosidases (Lagaert et al., 2010, 2014;
Rivière et al., 2014). The majority of the bifidobacterial strains
cannot use xylose backbones longer than xylotetraose, i.e., they
display a preferential metabolism, except for one strain among
the 36 tested ones, B. catenulatum LMG 11043T, that also uses
longer xylose backbones, i.e., they display a non-preferential
metabolism (Rivière et al., 2014). This could explain why the
bifidogenic effect is strongly influenced by the complexity of
the AXOS molecules and decreases with increasing DP (Table 2;
Van Craeyveld et al., 2008). A multivariate data analysis of the
fermentation data of these 36 bifidobacterial strains has revealed
five species-independent clusters, representing five different
complementary AXOS degradation mechanisms (Rivière et al.,
2014). Cluster I strains, albeit not all, consume free arabinose
and xylose; cluster II strains have an extracellular arabinose
substituent-oriented metabolism; cluster III strains display a
preferential metabolism of non-substituted xylose backbones;
cluster IV strains combine the degradation mechanisms of
clusters II and III; and cluster V strains display a non-preferential
AXOS metabolism. The complementary degradation mechanism
of bifidobacterial strains and the ability of intracellular and cell-
associated degradation of xylose backbones and AXOS, could
explain the selective stimulation of bifidobacteria by AXOS in
the presence of other saccharolytic colon bacteria in the human
colon. Whole-genome sequence annotations have revealed that
some bifidobacterial strains contain genes coding for enzymes
involved in the debranching of substituents and in the exo-
cleavage of the xylose backbones of AX and AXOS (Schell
et al., 2002; van den Broek and Voragen, 2008; van den
Broek et al., 2008). Indeed, several AXOS-degrading enzymes
have been isolated and characterized in bifidobacterial strains,
encompassing β-xylosidases in B. adolescentis ATCC 15703
and B. animalis subsp. lactis BB-12; α-arabinofuranosidases in
B. adolescentis ATCC 15703, B. adolescentis DSM 20083, B.
longum B667, and B. longum NCC2705; and exo-oligoxylanases
in B. adolescentis LMG 10502 (Lagaert et al., 2010, 2011, 2014).
However, up to now, no β-endoxylanases have been found in
the genome of bifidobacteria. The only gene (i.e., BL1543) that
was first annotated as a β-endoxylanase in B. longum NCC2705
(Schell et al., 2002) has shown to be an extracellular membrane-
associated α-arabinofuranosidase (Lagaert et al., 2010, 2014;
Rivière et al., 2014). For the complete utilization of AX, it is likely
that most of the Bifidobacterium species require cooperation
with β-endoxylanase-producing bacteria, such as Bacteroides and
Roseburia species (Chassard et al., 2007; Dodd et al., 2011).
For instance, the genome of R. intestinalis L1-82 contains
three genes possibly encoding β-endoxylanases (NCBI Resource
Coordinators, 2014).
Butyrogenic effects of AX and AXOS
Besides a bifidogenic effect, AX and AXOS have shown to
cause a butyrogenic effect (Table 2). In seven of the 13 in vitro
and in vivo studies summarized in Table 2, bifidobacteria and
butyrate-producing colon bacteria (F. prausnitzii, E. rectale, and
Roseburia spp.) are stimulated simultaneously, with a significant
increase of butyrate production as a result. As these butyrate-
producing colon bacteria are present in high numbers in the
colon, a rise in butyrate concentration does not come as a
surprise (De Vuyst et al., 2014). In contrast to bifidobacteria,
much less is known about the genetic AX- and AXOS-degrading
potential of species of butyrate-producing colon bacteria. In
silico analysis of the genome sequence of, for instance, E.
rectale ATCC 33656 has shown that there are five genes
possibly encoding AXOS-degrading enzymes (exo-oligoxylanase,
bifunctional β-xylosidase/α-arabinofuranosidase, β-xylosidase,
and two α-arabinofuranosidases; Rivière et al., 2015).
In contrast to ITF, the link between the consumption of
AXOS, the bifidogenic effect, and the butyrogenic effect has been
assessed only recently (Rivière et al., 2015). It has been shown
that a third type of cross-feeding can take place in the presence of
AXOS (Figure 4), for instance in the case of B. longumNCC2705
(an arabinose substituent degrader of AXOS) and E. rectale
ATCC 33656 (a complete AXOS degrader). Both strains consume
AXOS (as in cross-feeding type 1), but the bifidobacterial strain
is additionally stimulated by consuming the monosaccharides
released by the extracellular degradation of AXOS by the
E. rectale strain, leading to cross-feeding interactions that are
mutually beneficial (Figure 4). It is likely that these kinds of
cross-feeding interactions between bifidobacteria and butyrate-
producing colon bacteria, caused by prebiotic consumption, will
take place in vivo in the human colon (Boets et al., 2013).
However, the presence of other bacterial strains, with their
own mechanisms of carbohydrate degradation (preferential vs.
non-preferential) and own cross-feeding interactions within and
between species and genera (Figure 4), complicate the attempts
to fully understand the bifidogenic and butyrogenic effects of
AX and AXOS in the human colon. Furthermore, the inter-
individual variations in bacterial composition make it even more
intricate to predict the effects of prebiotic consumption in the
colon.
CONCLUSIONS
Human gut microbiota research has grown tremendously
over the last years in terms of technology development and
implications for human health. For instance, it has been shown
that certain key bacteria within the colon, such as bifidobacteria
and butyrate-producing colon bacteria, are negatively correlated
with disorders such as IBD and colorectal cancer. Of the same
importance is the progress that is beingmade into themodulation
of the gut microbiota through the use of probiotics, prebiotics,
and FMTs to improve human health. Whereas, in the past,
the focus was on straightforward increase of bifidobacterial cell
concentrations, shifts in interests are currently emphasizing that
the stimulation of butyrate-producing bacteria in the human
colon is of importance too. The consumption of prebiotic ITF
and AXOS seems to be a promising approach to counteract
decreased numbers of bifidobacteria and butyrate-producing
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colon bacteria. The challenge for the upcoming years will
however be to first find out whether these changes in gut
microbiota composition are the cause or the consequence of a
disorder.
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